Pharmaceutical Firms

Emcure Pharma surges 10%, stock hits new high on strong outlook

Analysts at Jefferies remain positive on Emcure Pharma's near- to mid-term outlook, supported by multiple growth drivers and operating-leverage benefits.

Compliance backlogs delay drug batch releases at pharma plants: Study

Vector Consulting survey finds manufacturing incident investigations taking up to six months to resolve, delaying drug batch releases and affecting productivity at pharma plants

Pharma industry seeks clarity on CDSCO solvent order's export ambit

Pharma executives seek clarity on export applicability of CDSCO's batch-wise solvent clearance rules, warning that approval delays could disrupt supplies, particularly in rural markets

ERP transformation key to ensuring pharma manufacturing continuity: Experts

Modernising pharma through enterprise resource planning (ERP) transformation replaces vulnerable legacy systems with a single source of truth, ensuring uninterrupted manufacturing continuity, according to experts. "This digital evolution gives life sciences companies the agility and data integrity needed to seamlessly meet strict regulatory requirements," Mandar Ghatnekar, Chief Technology Officer, Biocon, said while addressing the 15th edition of the Pharma IT Summit Mumbai 2026 organised by Exito Media Concepts earlier in the week. Speakers from top pharmaceutical companies, who attended the summit, also advocated for the need for human review of GenAI outputs, particularly in a good practice (GxP) environment. "In a highly regulated industry like pharmaceuticals, successful AI adoption requires a strong foundation of people, process, technology and governance, balancing innovation with regulatory compliance and operational excellence. "The future of AI will be defined not by how

Sun Pharma Q2 net profit falls 36% on one-time charges, revenue rises 12%

Exceptional charges of Rs 1,268.8 crore, including a US antitrust settlement and Organon acquisition costs, weighed on profit, while India formulation sales grew 17.3 per cent

Semaglutide mkt settles into steady growth six months after patent expiry

Generic brands now account for about 74% of monthly units as lower-priced products expand access, while doctors say the initial rush around the drug is cooling

Pharma haircare market in India finds its growth roots in young patients

Growth more than twice that of overall dermatology market; September sales surge 37.1% year-on-year, driven largely by higher volumes

Piramal Pharma cuts exposure to Chinese raw materials to reduce supply risk

Piramal is among global drugmakers increasingly seeking to reduce their reliance on China for pharmaceutical ingredients and manufacturing, amid rising geopolitical tensions

Sun Pharma board approves plan to raise up to ₹10,000 crore via NCDs

Sun Pharmaceutical Industries has said its board of directors has approved a proposal to raise funds of up to Rs 10,000 crore through the issuance of non-convertible debentures (NCDs). The decision was taken at a meeting of the company's Board of Directors held on October 12, Sun Pharma said in a regulatory filing late on Monday evening. The board approved the issuance of listed, rated, unsecured, redeemable NCDs on a private placement basis in one or more tranches and/or series for an aggregate amount not exceeding Rs 10,000 crore. The company said that disclosures required under Regulation 30 of the Sebi (Listing Obligations and Disclosure Requirements) Regulations, 2015, will be made at an appropriate stage upon the issuance or allotment of the debentures. Separately, the company announced that Gautam Doshi has resigned as a Non-Executive, Independent Director with immediate effect, citing personal reasons. Consequent upon his resignation, he has also ceased to hold positions on

IPM volume growth at 3.4% marks 2-yr high on steady demand across therapies

Volume growth reached 3.5 per cent, the highest in two years, while pricing rose about 6.2 per cent as most therapy segments recorded stronger demand

Nifty Pharma defies mkt slump, up 1% as select drugs exempt from US tariffs

Qualifying speciality medicines from India will be eligible for zero duty, providing some relief to Indian drugmakers with exposure to the US market.

AI-led drug discovery to create decade-long CDMO tailwind: Harini Dedhia

AI is a utility for pharma companies, delivering drug discovery in a shorter time frame with far higher chances of success.

Novartis India zooms 51% in 3 days; what's driving the pharma stock?

Novartis India acquired the Minipress and Minipres trademarks in India and certain related intellectual property rights from Pfizer Inc and Pfizer Products Inc for ₹1,250 crore.

Maharashtra FDA cancels Cipla C&F licences in Pune; firm contests order

State regulator cites alleged packaging, inventory and storage violations at Cipla's Pune C&F warehouse; company challenges order, says matter is sub judice

2 workers killed, 9 injured in reactor blast at Telangana pharma unit

Two workers were killed and nine others were injured in a reactor blast incident at a pharma company in Yadadri Bhuvanagiri district of Telangana, police said on Saturday. The incident occurred late on Friday night and triggered a fire in the unit located in Pochampally mandal when the workers were changing shift. "Two persons died. Nine people were injured, including two who suffered more than 50 per cent burns while seven sustained minor injuries", a police official told PTI. The injured were admitted to different hospitals, the official said. The fire was subsequently extinguished by the Fire Department. A case was registered and further investigation is on.

New launches, innovative portfolio set to drive gains for GSK Pharma stock

Brokerages expect strong near-term growth on traction in innovative products and new launches, though some see limited upside after the stock's recent outperformance

Moderna, Merck cancer vaccine scores big win in late-stage melanoma trial

Moderna and Merck's personalised mRNA vaccine met key goals in a Phase 3 melanoma trial, reducing recurrence and spread and raising hopes for a new generation of cancer vaccines worldwide

Ipca surges 11% in tepid market, nears 52-week high on healthy Q1 results

Ipca Laboratories upgraded FY27 revenue growth guidance to 14-16 per cent from 12-13 per cent and raised consolidated EBITDA margin guidance to 23 per cent from 22 per cent.

Kwality Pharma, Aarti Pharmalabs, Universal Cables hit 20% upper circuits

The share price of Kwality Pharmaceuticals hit a new high of ₹3,130.85 on Monday. The stock zoomed 183% thus far in the calendar year 2026.

Mukul Agrawal portfolio: Neuland Labs soars 10%, hits new high; here's why

In the past six months, the stock price of Neuland Labs outperformed the market by surging 68 per cent, as compared to 6 per cent decline in the BSE Sensex.